Asston Pharmaceuticals Ltd will hold an EGM on July 31, 2026, to approve raising ₹27.72 crore by issuing 24.10 lakh equity shares at ₹115 each to 15 non-promoter entities. Funds will boost working capital and reduce debt.
Asston Pharmaceuticals Plans ₹27.72 Crore Capital Raise via Preferential Issue
Asston Pharmaceuticals Limited will seek shareholder approval at an Extraordinary General Meeting (EGM) on July 31st, 2026, to raise approximately ₹27.72 crore through a preferential issue. The company plans to issue 24,10,431 equity shares at a price of ₹115 per share to 15 non-promoter entities.
What just happened
The board of Asston Pharmaceuticals has approved the issuance of 24,10,431 equity shares at ₹115 each, aggregating to ₹27.72 crore. This capital raise is subject to shareholder approval at the upcoming EGM.
Why this matters
This capital infusion will strengthen the company's financial position, with a significant portion allocated to incremental working capital. The issue price represents a premium over recent market trading averages, indicating confidence in the company's valuation. The shareholding structure will also see a shift, with public holding increasing.
The backstory
Asston Pharmaceuticals is a player in the pharmaceutical sector. This fundraising initiative is part of its strategy to enhance operational capabilities and financial health.
What changes now
Upon successful completion of the preferential issue, Asston Pharmaceuticals will have additional funds for working capital, debt repayment, and capital expenditure. The shareholding pattern will change, with promoters' stake diluting and public holding increasing.
Risks to watch
Investors should note that the utilization of funds for working capital and other purposes is based on internal estimates and may be subject to change. Effective deployment of the raised capital will be crucial for future growth.
Peer comparison
(No specific peer comparison data was available in the provided filing text.)
Context metrics (time-bound)
- Fundraising Target: ₹27.72 crore
- Shares to be issued: 24,10,431 equity shares
- Issue Price: ₹115 per share (a premium of ₹105 over face value)
- 10-Day VWAP: ₹69.79
- 90-Day VWAP: ₹75.60
- EGM Date: July 31st, 2026
What to track next
Investors will be keen to track the outcome of the EGM and the subsequent completion of the preferential allotment. Monitoring the utilization of the funds and the impact on the company's operational performance and financial metrics will be key.